Catalyst announces vamorolone Phase 1 data showing expected cortisol suppression without significant immunosuppression.
Catalyst Pharmaceuticals reported top-line Phase 1 data for vamorolone demonstrating balanced corticosteroid activity without evidence of immunosuppression. This validates the drug's differentiated safety profile for chronic inflammatory diseases.
View filing at SEC.gov →